Guidance for Safety and Dosing of Medicines in Patients With Cirrhosis Is Available.
作者信息
Weersink Rianne A, Drenth Joost P H, Hunfeld Nicole G M, Borgsteede Sander D
机构信息
Department of Pharmacotherapy, -Epidemiology, and -Economics University of Groningen Groningen the Netherlands.
Health Base Foundation Houten the Netherlands.
出版信息
Hepatol Commun. 2019 Jul 8;3(9):1281-1282. doi: 10.1002/hep4.1399. eCollection 2019 Sep.
Abstract
摘要
相似文献
1
Guidance for Safety and Dosing of Medicines in Patients With Cirrhosis Is Available.现已出台肝硬化患者用药安全及剂量指南。
Hepatol Commun. 2019 Jul 8;3(9):1281-1282. doi: 10.1002/hep4.1399. eCollection 2019 Sep.
2
Safe use of medication in patients with cirrhosis: pharmacokinetic and pharmacodynamic considerations.肝硬化患者的药物安全使用：药代动力学和药效学考虑因素。
Expert Opin Drug Metab Toxicol. 2020 Jan;16(1):45-57. doi: 10.1080/17425255.2020.1702022. Epub 2019 Dec 11.
3
Evaluation of Information in Summaries of Product Characteristics (SmPCs) on the Use of a Medicine in Patients With Hepatic Impairment.药品说明书（SmPCs）中关于肝功能损害患者用药信息的评估
Front Pharmacol. 2019 Sep 17;10:1031. doi: 10.3389/fphar.2019.01031. eCollection 2019.
4
Evaluating the safety and dosing of drugs in patients with liver cirrhosis by literature review and expert opinion.通过文献回顾和专家意见评估肝硬化患者的药物安全性和剂量。
BMJ Open. 2016 Oct 12;6(10):e012991. doi: 10.1136/bmjopen-2016-012991.
5
Patients' ability to read and understand dosing instructions of their own medicines - a cross sectional study in a hospital and community pharmacy setting.患者阅读和理解自身药品用药说明的能力——一项在医院和社区药房环境中的横断面研究。
BMC Health Serv Res. 2018 Jun 7;18(1):425. doi: 10.1186/s12913-018-3252-1.
6
Evidence-Based Recommendations to Improve the Safe Use of Drugs in Patients with Liver Cirrhosis.循证推荐意见以改善肝硬化患者的药物安全使用。
Drug Saf. 2018 Jun;41(6):603-613. doi: 10.1007/s40264-017-0635-x.
7
A study of the use of medicine lists in medicines reconciliation: please remember this, a list is just a list.一项关于用药清单在药物重整中应用的研究：请记住这一点，清单仅仅只是个清单。
Int J Pharm Pract. 2010 Apr;18(2):116-21.
8
[Guidance for education on medicines in school].[学校药品教育指南]
Yakugaku Zasshi. 2013;133(12):1319-23. doi: 10.1248/yakushi.13-00226-3.
10
The European Herbal Medicines Directive: could it have saved the lives of Romeo and Juliet?《欧洲草药产品指令》：它能挽救罗密欧与朱丽叶的生命吗？
Drug Saf. 2008;31(5):416-8. doi: 10.2165/00002018-200831050-00006.
引用本文的文献
1
Reply.回复。
Hepatol Commun. 2019 Jul 10;3(9):1283-1284. doi: 10.1002/hep4.1398. eCollection 2019 Sep.
本文引用的文献
1
Medication-Related Problems in Outpatients With Decompensated Cirrhosis: Opportunities for Harm Prevention.失代偿期肝硬化门诊患者的药物相关问题：预防危害的机会
Hepatol Commun. 2019 Mar 18;3(5):620-631. doi: 10.1002/hep4.1334. eCollection 2019 May.
2
Prevalence of Drug Prescriptions and Potential Safety in Patients with Cirrhosis: A Retrospective Real-World Study.肝硬化患者的药物处方和潜在安全性：一项回顾性真实世界研究。
Drug Saf. 2019 Apr;42(4):539-546. doi: 10.1007/s40264-018-0744-1.
3
Evidence-Based Recommendations to Improve the Safe Use of Drugs in Patients with Liver Cirrhosis.循证推荐意见以改善肝硬化患者的药物安全使用。
Drug Saf. 2018 Jun;41(6):603-613. doi: 10.1007/s40264-017-0635-x.
4
Influence of liver cirrhosis on sertraline pharmacokinetics.肝硬化对舍曲林药代动力学的影响。
Br J Clin Pharmacol. 1996 Sep;42(3):394-7. doi: 10.1046/j.1365-2125.1996.42817.x.
Zotero 插件